Public companyCompany profile · informational
Illumina
Illumina makes DNA sequencing instruments, reagents and software used widely in research and clinical genomics. It acquired GRAIL in 2021 and separated from it in 2024 following regulatory challenges.
Verified highlights each with its source
- Illumina launched the NovaSeq X and NovaSeq X Plus high-throughput sequencers in September 2022.
Source: en.wikipedia.org ↗ - Illumina completed the spin-off of GRAIL in June 2024, retaining a minority stake of about 14.5%.
Source: en.wikipedia.org ↗
Sources
- en.wikipedia.orgen.wikipedia.org
- en.wikipedia.orgen.wikipedia.org
Science and stocks are different questions. This profile describes scientific and regulatory progress. It says nothing about whether the company’s shares will rise or fall, and it is not a recommendation to buy, sell or hold any security.
Disclosure. Spin Pharma has no financial relationship with this company and holds no position in it.
